A greater proportion of patients treated with Tremfya for moderate to severe ulcerative colitis achieved clinical remission at 12 weeks compared with placebo, according to Axel Dignass, MD, PhD, presenting author of a clinical study.
Data from the phase 2b QUASAR induction study showed more than 60% of patients treated with Tremfya (guselkumab, Janssen) achieved the primary endpoint of clinical response at week 12, with 30% of patients also achieving endoscopic improvement.
“This promising and exciting QUASAR study shows that in patients with moderately to severely active UC, guselkumab